Genentech Inc. has applied for U.S. (FDA) approval to market its drug Lucentis for the treatment of wet, age-related macular degeneration, the leading causes of blindness in the elderly.
Genentech requested priority basis review which if approved will give FDA six months to decide on drug approval.
Lucentis, if approved, will compete with Visudyne, made by Canada's QLT Inc., and Macugen, made by Pfizer Inc. and OSI Pharmaceuticals Inc.
Genentech's application is based on the results of late-stage clinical trials which showed that 95 percent of patients treated with Lucentis either maintained or improved their vision compared to 64 percent of those taking Visudyne.
Age-related macular degeneration affects about 1.7 million people in the United States. While the dry form of the disease is the most common, accounting for about 90 percent of all cases, the wet form is the most devastating.
Patients can go blind within a matter of days of developing the condition, caused by the build-up and rupture of too many blood vessels behind the eye.
Source: CNN
Filed under Eye Treatment, Macular Degeneration | Tags: eye | Comment Below
Related?
Most expensive drug "Lucentis" now available through cost effective scheme by NICE August 27th, 2008 National Institute For Clinical Excellence (NICE) has launched a special scheme which will help people suffering from macular degeneration to avail Novartis AG's, pricey eye drug Lucentis through cost effective scheme. This move, follows a draft plan in which the National Health Service will pay for a maximum of 14 injections of Lucentis per eye, with Novartis agreeing to pay if any more are needed.
Eye Drug Lucentis Recommended by UK's NICE to Treat Wet AMDJune 14th, 2007 Novartis AG's Lucentis drug against wet age-related macular degeneration (AMD) received a recommendation from the UK's National Institute for Health and Clinical Excellence (NICE) for use on the National Health Service. Lucentis should be used for about 20 pct of patients with AMD, a condition which causes sight loss and blindness, when both eyes are affected, NICE said in a statement last night.
Brand New Treatment For Macular DegenerationJuly 8th, 2006 It's the leading cause of blindness in people over the age of 50 and in our Healthy Living report a brand new treatment for Macular Degeneration that some are calling a miracle. Margie Puslipher suffers from Macular Degeneration and was on the verge of blindness.
Macular Degeneration and its New Treatments October 11th, 2006 The results of two large, randomized clinical trials published October 5, 2006, in the New England Journal of Medicine demonstrate that the drug ranibizumab (Lucentis) is an effective treatment for neovascular macular degeneration, a complication of age-related macular degeneration that leads to the vast majority of legal blindness associated with the disorder. it is a disease of the retina that affects more than 9 million Americans and is a leading cause of blindness in people over 55.
Midwest Eye Institute Doctor Helps To Test Drug For Macular Degeneration June 8th, 2008 The Macular degeneration is the type of eye disease that develops in the older people. It is one of the major causes of vision loss in countries like the USA, especially among the age group of 65 and above.
Wet-AMD patients may improve their near vision by Ranibizumab(Lucentis)May 8th, 2009 Now people who are suffering from wet-age- related-macular-degeneration can improve there hyperopia (farsightedness). The ability to read a newspaper or even prepare a meal functions require near-vision.
Age-Related Macular Degeneration Can Be Avoided By Taking NutrientsSeptember 15th, 2007 Researchers concluded that eating yellow and green vegetables may help people aged 60 and older avoid age-related macular degeneration, a leading cause of blindness. They have conducted a new study of some 4,500 people aged 60-80 who were screened for age-related macular degeneration, which hampers central vision.
Lucentis - Wet Macular Degeneration Drug is Highly Successful in Clinical TrialsJune 14th, 2006 Michels, a Palm Beach Gardens, Fla., ophthalmologist, has been treating some patients afflicted by the wet form of the disease with Lucentis, a Genentech Inc. drug that was placed on fast-track review by the Food and Drug Administration and could be approved this month.
January 17th, 2008 at 4:59 am
Is er ook al een geneesmiddel voor droge macula-degeneratie verkrijgbaar???
April 13th, 2008 at 7:19 pm
This drug has been approved for use now in many countries. It is a major advancement.
The CDR here in Canada has just recommended that the provincial health care programs throughout Canada should provide coverage for this drug.
However, I do question why Lucentis & Avastin are priced so differently.